EyePoint’s Partner Betta Completes Enrollment for Duravyu’s Pivotal Phase III Study
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), the US partner of China-based Betta Pharmaceuticals (SHE: 300558), announced...
EyePoint Pharmaceuticals
Betta Pharmaceuticals’ EYP-1901 Implant Secures NMPA Clinical Trial Nod for Wet AMD
Betta Pharmaceuticals (SHE: 300558) has announced that it has received clinical trial approval from China’s...
EyePoint Pharmaceuticals’ Durvayu Fails to Meet Primary Endpoint in NPDR Trial
EyePoint Pharmaceuticals Inc., (NASDAQ: EYPT) has announced that its drug candidate Durvayu (vorolanib intravitreal insert;...
Ocumension Therapeutics Sells $56.66 Million Stake in EyePoint Pharmaceuticals
Ocumension Therapeutics (HKG: 1477), a specialist in the ophthalmology sector in China, has announced plans...
Betta Pharmaceuticals and EyePoint Pharmaceuticals Submit EYP-1901 for NMPA Review
China’s Betta Pharmaceuticals (SHE: 300558) has announced that the clinical trial filing for its EYP-1901...